​

ARS Pharmaceuticals (SPRY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SPRY Stock Forecast

ARS Pharmaceuticals (SPRY) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $32.00, with a high of $32.00 and a low of $32.00. This represents a 240.79% increase from the last price of $9.39.

$5 $11 $17 $23 $29 $35 High: $32 Avg: $32 Low: $32 Last Closed Price: $9.39

SPRY Stock Rating

ARS Pharmaceuticals stock's rating consensus is Hold, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 3 Buy (30.00%), 6 Hold (60.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 10 0 6 3 1 Strong Sell Sell Hold Buy Strong Buy

SPRY Price Target Upside V Benchmarks

TypeNameUpside
StockARS Pharmaceuticals240.79%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$32.00$32.00
Last Closing Price$9.39$9.39$9.39
Upside/Downside-240.79%240.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2515---6
Sep, 2515---6
Aug, 2515---6
Jul, 2515---6
Jun, 2515---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 26, 2025Raymond James$32.00$9.69230.24%240.79%
Aug 19, 2024Josh SchimmerCantor Fitzgerald$30.00$14.24110.67%219.49%
Aug 12, 2024Strong BuyRaymond James$22.00$10.85102.76%134.29%
Jul 25, 2024Ryan DeschnerRaymond James$18.00$10.4073.08%91.69%
Mar 05, 2024Roanna RuizLeerink Partners$18.00$8.65108.09%91.69%
Dec 13, 2022Leerink Partners$14.00$7.1296.63%49.09%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2025Roth CapitalBuyinitialise
Mar 07, 2025ScotiabankOutperforminitialise
Jan 14, 2025Raymond JamesStrong BuyStrong Buyhold
Oct 08, 2024Raymond JamesStrong BuyStrong Buyhold
Sep 09, 2024Raymond JamesStrong BuyStrong Buyhold
Aug 19, 2024Cantor FitzgeraldOverweightinitialise
Aug 12, 2024Raymond JamesOutperformStrong Buyupgrade
Jul 25, 2024Raymond JamesOutperforminitialise
Mar 05, 2024Leerink PartnersOutperformupgrade
Feb 20, 2024William BlairMarket PerformOutperformupgrade

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.85$-0.57$0.08----
Avg Forecast$-0.94$-0.61$-0.55$-0.35$0.05$0.51$1.32
High Forecast$-0.39$-0.58$-0.15$0.75$0.17$0.57$2.27
Low Forecast$-1.84$-0.64$-0.73$-1.28$-0.01$0.45$0.74
Surprise %-9.57%-6.56%-114.55%----

Revenue Forecast

$0 $160M $320M $480M $640M $800M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.32M$30.00K$89.15M----
Avg Forecast$1.27M$10.00K$20.26M$122.35M$215.62M$311.88M$485.03M
High Forecast$2.20M$15.48K$35.12M$186.24M$333.71M$311.88M$750.69M
Low Forecast$693.42K$6.61K$5.39M$79.49M$142.43M$311.88M$320.40M
Surprise %3.76%200.00%340.05%----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.99M$-54.37M$8.00M----
Avg Forecast$-89.56M$-58.37M$-49.10M$-34.68M$7.44M$48.56M$126.00M
High Forecast$-36.78M$-55.64M$-14.55M$71.27M$15.93M$54.27M$215.72M
Low Forecast$-174.93M$-61.11M$-69.11M$-122.17M$-1.05M$42.85M$70.40M
Surprise %-62.05%-6.87%-116.29%----

SPRY Forecast FAQ

Is ARS Pharmaceuticals stock a buy?

ARS Pharmaceuticals stock has a consensus rating of Hold, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 3 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ARS Pharmaceuticals is a neutral investment for most analysts.

What is ARS Pharmaceuticals's price target?

ARS Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $32 over the next 12 months. The price target range spans from $32 at the low end to $32 at the high end, suggesting a potential 240.79% change from the previous closing price of $9.39.

How does ARS Pharmaceuticals stock forecast compare to its benchmarks?

ARS Pharmaceuticals's stock forecast shows a 240.79% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ARS Pharmaceuticals over the past three months?

  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ARS Pharmaceuticals’s EPS forecast?

ARS Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.35, marking a -537.50% decrease from the reported $0.08 in 2024. Estimates for the following years are $0.05 in 2026, $0.51 in 2027, and $1.32 in 2028.

What is ARS Pharmaceuticals’s revenue forecast?

ARS Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $122.35M, reflecting a 37.24% increase from the reported $89.15M in 2024. The forecast for 2026 is $215.62M, followed by $311.88M for 2027, and $485.03M for 2028.

What is ARS Pharmaceuticals’s net income forecast?

ARS Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-34.679M, representing a -533.59% decrease from the reported $8M in 2024. Projections indicate $7.44M in 2026, $48.56M in 2027, and $126M in 2028.